A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer (PREVAIL)
PREVAIL: A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study
of Oral MDV3100 in Chemotherapy-Naïve Patients With Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy
Category & Conditions: Cancer
Medicine: Xtandi (enzalutamide)
ClinicalTrials.gov Identifier (NCT): NCT01212991
Protocol ID: C3431003
PrintDownloadOpen Plain Language Summary Result: Click here